Payment overview · 2025
General Payments
$1,718.83
80 reported records · 14 companies
Healthcare provider profile · identity verified
Nilar Tun
Allopathic & Osteopathic Physicians|General Practice · NEW YORK, NY · NPI 1942621263
Verified facts
What the public records show
CMS Open Payments records show Nilar Tun received $1,718.83 in general payments during 2025 across 80 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Airsupra, Creon, Farxiga, Linzess, Nexletol, Ozempic, Prolia, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 304 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Nexlizet by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tresiba by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $335.35 | 19.5% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $253.54 | 14.8% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $240.43 | 14.0% | 12 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $166.54 | 9.7% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $157.71 | 9.2% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $143.28 | 8.3% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $97.38 | 5.7% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $94.99 | 5.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.96 | 4.1% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.37 | 3.3% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $34.65 | 2.0% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.45 | 1.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.08 | 1.3% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.10 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,718.83 | 80 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $247.45 | 8 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $217.43 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $173.68 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $157.71 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $143.28 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $97.38 | 5 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $94.99 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $69.96 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $69.96 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $57.37 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $46.10 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.67 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $34.65 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $6.09 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $6.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 14 | exact normalized | Medicare Part D |
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 304 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 256 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 82 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 197 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 121 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
256 | 55 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
82 | 60 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
304 | 60 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
136 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
91 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
33 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
121 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
197 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 1461 | 265 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1119 | 210 |
| Amlodipine Besylate | Amlodipine Besylate | 721 | 138 |
| Losartan Potassium | Losartan Potassium | 688 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 609 | 121 |
| Tamsulosin Hcl | Tamsulosin Hcl | 525 | 108 |
| Gabapentin | Gabapentin | 473 | 148 |
| Omeprazole | Omeprazole | 447 | 127 |
| Metoprolol Succinate | Metoprolol Succinate | 413 | 86 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 406 | 75 |
| Famotidine | Famotidine | 354 | 108 |
| Simvastatin | Simvastatin | 327 | 67 |
| Finasteride | Finasteride | 312 | 66 |
| Diclofenac Epolamine | Diclofenac Epolamine | 306 | 64 |
| Farxiga | Dapagliflozin Propanediol | 304 | 60 |
| Jardiance | Empagliflozin | 302 | 52 |
| Montelukast Sodium | Montelukast Sodium | 300 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 294 | 88 |
| Diclofenac Sodium | Diclofenac Sodium | 269 | 112 |
| Donepezil Hcl | Donepezil Hcl | 258 | 55 |
| Linzess | Linaclotide | 256 | 55 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 232 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 221 | 124 |
| Ammonium Lactate | Ammonium Lactate | 208 | 80 |
| Alendronate Sodium | Alendronate Sodium | 200 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 197 | 40 |
| Metformin Hcl | Metformin Hcl | 197 | 39 |
| Rybelsus | Semaglutide | 197 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 185 | 40 |
| Nebivolol Hcl | Nebivolol Hcl | 170 | 34 |
| Synjardy | Empagliflozin/Metformin Hcl | 170 | 30 |
| Glipizide Er | Glipizide | 164 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 162 | 42 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 161 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 36 |
| Acarbose | Acarbose | 157 | 32 |
| Azelastine Hcl | Azelastine Hcl | 144 | 60 |
| Allopurinol | Allopurinol | 142 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 140 | 25 |
| Nexium | Esomeprazole Magnesium | 136 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 127 | 65 |
| Eliquis | Apixaban | 126 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 59 |
| Repaglinide | Repaglinide | 121 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 121 | 24 |
| Meloxicam | Meloxicam | 120 | 73 |
| Ropinirole Hcl | Ropinirole Hcl | 120 | 30 |
| Xarelto | Rivaroxaban | 120 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 45 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 117 | 26 |
| Mometasone Furoate | Mometasone Furoate | 114 | 63 |
| Myrbetriq | Mirabegron | 109 | 27 |
| Januvia | Sitagliptin Phosphate | 108 | 23 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 107 | 43 |
| Metformin Hcl Er | Metformin Hcl | 105 | 28 |
| Meclizine Hcl | Meclizine Hcl | 104 | 54 |
| Azithromycin | Azithromycin | 103 | 89 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 103 | 49 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 102 | 23 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 98 | 47 |
| Dexlansoprazole Dr | Dexlansoprazole | 97 | 25 |
| Mupirocin | Mupirocin | 96 | 58 |
| Ketoconazole | Ketoconazole | 94 | 24 |
| Vemlidy | Tenofovir Alafenamide | 91 | 14 |
| Mirtazapine | Mirtazapine | 86 | 28 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 86 | 19 |
| Prolia | Denosumab | 82 | 60 |
| Glimepiride | Glimepiride | 80 | 17 |
| Colchicine | Colchicine | 79 | 21 |
| Lansoprazole | Lansoprazole | 79 | 18 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 77 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 75 | 36 |
| Atenolol | Atenolol | 73 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 69 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 19 |
| Ezetimibe | Ezetimibe | 65 | 15 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 64 | suppressed |
| Naproxen | Naproxen | 62 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 12 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 60 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 51 |
| Fluocinonide | Fluocinonide | 59 | 33 |
| Icosapent Ethyl | Icosapent Ethyl | 59 | 25 |
| Memantine Hcl | Memantine Hcl | 58 | 18 |
| Lidocaine | Lidocaine | 56 | 21 |
| Fenofibrate | Fenofibrate | 55 | 17 |
| Amoxicillin | Amoxicillin | 52 | 41 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 52 | 12 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 52 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 51 | suppressed |
| Entecavir | Entecavir | 50 | suppressed |
| Loperamide | Loperamide Hcl | 49 | 26 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 47 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 19 |
| Raloxifene Hcl | Raloxifene Hcl | 46 | 11 |
| Bepotastine Besilate | Bepotastine Besilate | 45 | 22 |
| Dutasteride | Dutasteride | 45 | 14 |
| Glipizide | Glipizide | 45 | 11 |
| Hydrocortisone | Hydrocortisone | 44 | 32 |
| Potassium Chloride | Potassium Chloride | 44 | 19 |
| Clobetasol Propionate | Clobetasol Propionate | 42 | 26 |
| Pregabalin | Pregabalin | 42 | 13 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 41 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 40 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 40 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 14 |
| Baclofen | Baclofen | 37 | 24 |
| Restasis | Cyclosporine | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Ibuprofen | Ibuprofen | 35 | 28 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 35 | 11 |
| Celecoxib | Celecoxib | 34 | 20 |
| Lorazepam | Lorazepam | 34 | 21 |
| Ozempic | Semaglutide | 34 | suppressed |
| Procto-Med Hc | Hydrocortisone | 34 | 21 |
| Tradjenta | Linagliptin | 34 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 33 | 14 |
| Clotrimazole | Clotrimazole | 33 | 12 |
| Nystatin | Nystatin | 33 | 21 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 33 | 16 |
| Single Use Swab | Alcohol Antiseptic Pads | 33 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 31 | 12 |
| Calcitriol | Calcitriol | 31 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 31 | 23 |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Furosemide | Furosemide | 31 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | 21 |
| Cephalexin | Cephalexin | 29 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | 15 |
| Alcohol Pads | Alcohol Antiseptic Pads | 26 | 16 |
| Creon | Lipase/Protease/Amylase | 26 | suppressed |
| Folic Acid | Folic Acid | 26 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 26 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Prednisone | Prednisone | 26 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 24 |
| Clonazepam | Clonazepam | 25 | suppressed |
| Nexletol | Bempedoic Acid | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 14 |
| Valsartan | Valsartan | 24 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 23 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | 11 |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Ciclopirox | Ciclopirox | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | 17 |
| Airsupra | Albuterol Sulfate/Budesonide | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lisinopril | Lisinopril | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Bystolic | Nebivolol Hcl | 17 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 17 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 14 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Ztlido | Lidocaine | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 13 | suppressed |
| Flector | Diclofenac Epolamine | 13 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Vesicare | Solifenacin Succinate | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Glipizide Xl | Glipizide | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Tacrolimus | Tacrolimus | 11 | suppressed |
| Tresiba | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,718.83 · 80 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, CREON, EVENITY, FARXIGA, GEMTESA, IBSRELA, Kerendia, LINZESS, NEXLETOL, OTEZLA, Ozempic, PREVNAR 20, PROLIA, PYRUKYND, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, ZORYVE | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error